Experiences with
Venetoclax1,057 public posts
CLL Patient Survey
If you have CLL and have been treated with either ibrutinib (Imbruvica) or venetoclax (ABT-199) we need your help.
Want to take advantage of all our features? Just log in!
or
Venetoclax in Relapsed deletion 17 CLL
We discussed his late breaking abstract on venetoclax in refractory CLL patients with deletion 17p. You can see a summary and view our interview here.
ASH 2015: Dr. Jones on combining venetoclax with obinutuzumab, and details about the LRF meeting this weekend and new CLL support groups
We discussed the data for patients with relapsed/refractory CLL on combining the BCL-2 (B-cell lymphoma-2) inhibitor venetoclax with the antibody obinutuzumab, the ongoing European trials and a new study that adds ibrutinib to that mix. You can see a summary and view our interview here.
Venetoclax (ABT-199) response rate on del 17p CLL patients (ASH 2015)
Venetoclax is an orally bioavailable, selective BCL-2 inhibitor that induces apoptosis in CLL cells independent of p53. A phase 1 study of Venetoclax showed high response rates in patients with relapsed/refractory CLL, including del(17p) CLL (overall response rate, ORR = 77%).
The Role of BCL2 Inhibition in CLL
Friends,
To understand why BCL-2 is such an attractive target in CLL and with the promise of venetoclax (ABT-199) hopefully coming soon, here is the very easy to digest nine minute lecture given by Dr.
Integrating Emerging Evidence Into the Management of CLL Patients; what leading CLL experts recommend in 4 case studies
(Second Generation BCL-2 inhibitor)
Venetoclax + Rituximab
and of course..
The Future Role of FCR and new data on venetoclax and rituximab
We also share my comments and background on an important oral abstract presented at the 20th Congress of the European Hematology Association (EHA), June 11-15, 2015 on venetoclax (ABT-199 or GDC-199) and rituximab.
For Refractory CLL, Venetoclax's (ABT-199's) Complete Response Rate Is Tops
The complete response rate seen with venetoclax is especially notable, said lead investigator Andrew W. Roberts, MBBS, PhD, from the Royal Melbourne Hospital and Walter and Eliza Hall Institute of Medical Research, in Australia."
Venetoclax (ABT-199) Receives Breakthrough Therapy Designation In Relapsed Or Refractory CLL In Previously Treated 17p deletion Patients
This breakthrough designation - only for relapsed/refractory 17p deletion patients should mean the path to FDA approval will be smooth and short in the USA. This is very good news for my fellow American patients with 17p del. Hope the rest of the world stays in step.
We are only going to beat this cancer
Assessing Response With Novel Agents in CLL - OncLive Peer Exchange
Kipps, MD, UCSD; Shuo Ma, MD, PhD, Northwestern
http://www.onclive.com/peer-exchange/non-hodgkins-lymphoma/Assessing-the-Utility-of-MRD-Measures-Versus-CT-Scans
The discussion covers:
- Inhibition of Rituximab by Ibrutinib
- ABT-199 (Venetoclax) - ABT-199's remarkable ability to get complete remission
Venetoclax(ABT-199)/rituximab achieved an Overall Rate of Response of 88%
(ABT-199)Plus Rituximab Well Tolerated With Promising Activity in Patients With Relapsed/Refractory CLL
Venetoclax/rituximab achieved ORR of 88% in early investigation and 400 mg identified as the recommended dose for future studies.
http://www.clinicaloptions.com/Oncology/Conference